The Value of Molecular Profiling and Genetic Testing
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random and not inherited by her children.
Targeted Therapy to Inhibit Connective Tissue Growth in Pancreatic Cancer
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Harnessing the Power of Radionuclide Therapy
Julie Sutcliffe is working with targeted radionuclide therapy to go after pancreatic cancer cells that have spread beyond the pancreas.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Targeted Therapy for Pancreatic Cancer
Dr. Margaret Tempero outlines the work being done in the area of targeted therapy for pancreatic cancer, specifically the testing of ibrutinib.